Top stories from 2023 by the NPR Network : NPR
Here are the stories that captured your attention in 2023 from NPR.org and across the NPR Network.
Source: npr.org
📰 Published April News
Page 7 - Published April News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Published April. Real-time updates on events, politics, business and more.
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...
San Antonio United States Comunidad Autonoma De Cataluna France General Prnewswire Novartis Jeff Legos
Source: prnewswire.com
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...
United Kingdom Schleswig Holstein Martin Reck Alan Sandler Committee For Medicinal Products Human Use Healthcare Products Regulatory Agency
Source: marketscreener.com
Trastuzumab Biosimilar Use Significantly Increasing in the US
Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.
United States Herceptin Biosimilar Mai Xiaodan Trastuzumab Biosimilar Biologics Biosimilars Collective Intelligence Consortium Harvard Pilgrim Health Care Institute
Source: hcplive.com
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced the United Kingdoms Medicines and Healthcare...
United Kingdom Great Britain Alan Sandler Healthcare Products Regulatory Agency Exchange Commission Prnewswire Mirati Therapeutics Inc
Source: marketscreener.com
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdoms Medicines and...
United Kingdom Great Britain Alan Sandler University Hospital Birmingham Healthcare Products Regulatory Agency Prnewswire Mirati Therapeutics Inc
Source: prnewswire.com
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...
Source: marketscreener.com
Is ChatGPT Smarter Than a PCP?
ChatGPT performed well ― but not quite well enough ― on the UKs National Primary Care examinations, highlighting its lack of experience-based analysis as well as a tendency to hallucinate.
United Kingdom Glasgow City Sandip Pramanik Arun James Thirunavukarasu Shathar Mahmood Royal College
Source: medscape.com
The Impact of Medicaid Telehealth Policy Change on Equitable Access to Telehealth Services in NC | Manatt, Phelps & Phillips, LLP
Editor’s Note: In a new issue brief published by the Milbank Memorial Fund and summarized below, Manatt Health and leadership from the North Carolina Department of Health and Human...
United States North Carolina Turner Lee Phelps Phillips Health Affairs Blog American Immigration Council
Source: jdsupra.com
The Challenge of Making Cancer Trials More Diverse
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
United States University Of Pennsylvania Oluwadamillola Lola Fayanju Penn Abramson Cancer Center Society Of Surgical Oncology Annual Meeting Drug Administration
Source: oncologynurseadvisor.com